Article
Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.
Journal of pharmaceutical sciences - 1 Sept 2017
Wu Hsin-Fang, Hristeva Nadya, Chang Jae, Liang Xiaorong, Li Ruina, Frassetto Lynda, Benet Leslie Z
Abstract excerpt
The Food and Drug Administration recommends rosuvastatin dosage reductions in Asian patients because pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin in Asian subjects compared with Caucasian controls. Yet, no explanation for this ethnic difference has been confirmed. Here we show that rosuvastatin exposure in Asians and Whites does not differ...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.